Polo2024
Posted - 3 hours ago
$ASRT seeing a lot of single trades
Vavavoom
Posted - 7 hours ago
$ASRT https://www.nbcnews.com/health/cancer/cancer-drug-shortages-14-medicines-now-short-supply-fda-says-rcna86106
So if the shortage gets better, expect more use of rolvedon ( and all other neulesta biosimilars) and improved revenue
Swiss_Scroogy_McDuck
Posted - 8 hours ago
$ASRT I will revisit at USD 3. Market cap of 80 million, with USD 73 million cash n hand and generating 25% of current market cap in free cash flow - and people chasing tech and bio firms that have PE of 70-90
Jizzle14
Posted - 23 hours ago
$ASRT watching algos at wrk right now...
Ajwpdc
Posted - 1 day ago
$ASRT Correction, its gonna pop today
Ajwpdc
Posted - 1 day ago
$ASRT It looks like its gonna pop this week
D_S
Posted - 3 days ago
$ASRT Company will be reporting Q1 results around May 7th (date approx). Company will then be reporting at JMP Securities Life Sciences Conference for investors on May 13th: https://investor.assertiotx.com/events-and-presentations/events/event-details/2024/Citizens-JMP-Life-Sciences-Conference-2024-F-uY6JANjN/default.aspx
ElijahJobs
Posted - 3 days ago
$ASRT $COST $MCRB $SPY $TSLA So true! LOL
EpicPawnRaider
Posted - 3 days ago
$TSLA $COST $SPY $ASRT $MCRB
Chuckuk
Posted - 4 days ago
$ASRT Market Date FINRA FINRA FINRA FINRA FINRA Non-Exempt Volume Exempt Volume Short Volume Total Volume Short Volume Ratio 18/04/2024 200,959 + 0 = 200,959 / 356,063 = 56.44 17/04/2024 236,048 + 0 = 236,048 / 498,834 = 47.32 16/04/2024 120,156 + 0 = 120,156 / 260,940 = 46.05 15/04/2024 266,899 + 1,090 = 267,989 / 390,411 = 68.64 12/04/2024 169,435 + 0 = 169,435 / 282,084 = 60.07 11/04/2024 119,559 + 22,850 = 142,409 / 438,280 = 32.49 10/04/2024 188,418 + 250 = 188,668 / 306,434 = 61.57 09/04/2024 236,007 + 200 = 236,207 / 359,147 = 65.77 08/04/2024 80,626 + 3,250 = 83,876 / 170,167 = 49.29 05/04/2024 112,760 + 0 = 112,760 / 207,454 = 54.35
zoomlik
Posted - 4 days ago
$ASRT Asrt issue 36M shares for Rolv .. at 75 cents , it is like buying Rolv for $27M .. you guys are getting a deal here
zoomlik
Posted - 4 days ago
$ASRT Wow $72M market cap and $75M cash
Fearnot
Posted - 4 days ago
$ASRT thx for the cheapies reloading
PeoplesHernandez
Posted - 4 days ago
$ASRT Hard to believe there are sellers at this low of a price. Super undervalued.
D_S
Posted - 5 days ago
$ASRT people are talking about reverse splits to deal with current stock price? Foolish. Uh, how's this for an idea-----ASRT has $30M in cash above and beyond debt. If they show they can keep their operations cashflow positive (forecasting $20M+ in more cash build up in 2024) then they can just do a stock buy back. One of the cheapest companies they can buy right now with their cash is their own! lol. A $10M stock buy back announcement later (no need for it now, later only if stock is below $1) can easily move everything up. That's the security under this stock at this price. The company themselves can easily get the stock over $1 without help. What they need first is a new CEO.
buymoremakemore
Posted - 5 days ago
$ASRT just stay down for another week so I can play that earnings run up.
okhello1
Posted - 5 days ago
$ASRT Will it file bk soon? Because the price is dismal.
gain100percent
Posted - 5 days ago
$ASRT shorts have taken hold
ZonataTwits
Posted - 5 days ago
$ASRT so XBI has been tanking for a while... this imo is a great opportunity to add again. I like cash rich biotechs and I do believe the bio bull run will happen in 2024 or early 2025.
danmartinvela
Posted - 5 days ago
$ASRT Someone please explain it to me (screenshot), I'm new to pharmaceutical companies, and I like the set-up that we have here. Cash generation and low mcap. I'll drop some qs. 1. Why are they currently headless? For how long? Risky? 2. What's the actual oppo for Rolvedon, I mean, right now? 3. No acquisitions before the new CEO? 4. What can 100m USD buy in pharma land? Let's say at FY2024's end... 5. How good is Rolvedon? How much did they pay for it? I've read they overpaid for it, an expensive life jacket. 6. Is there any big potential for the remaining drugs? 7. I have read, on this chat, that every R unit costs 2-3k. Is that correct/verified?
Avedisian
Posted - 5 days ago
$ASRT Analyst est of avg rev is 29.5m, high rev is 31m Base revenue of 10m(Otrexup, Sympazan et.al), 6.2m from Indocin a total of 16.2m is set For Rolvedon revs: if you assume same price as Q4 then 13.5% higher shipped units should total 11m(Q4) * 1.1345 = 12.5m, a total of 28.7m But its not same price, check Q3 7090 units is 7m, Q4 7040 units is 11m, the price seems to be 50% higher so the price varies based on channel stuffing. If you assume various price improvements, you get various possible Rolvedon revs: 10% higher >>> 12.5*1.1 13.75m total 29.95m 20% higher >>> 12.5*1.2 15.00m total 31.2m 30% higher >>> 12.5*1.3 16.25m total 32.45 40% higher >>> 12.5*1.4 17.50m total 33.7m 50% higher >>> 12.5*1.5 18.75m total 34.95m Looks to me 15m is possible for total of 31.2m
Avedisian
Posted - 5 days ago
$ASRT Got Symphony Indocin nos for Q1 2024 Inst packed units as follows: Q1 = 192 + 181 + 217 = 590 Q4 = 267 + 372 + 390 = 1029(is 10.8m) Q3 = 486 + 664 + 759 = 1909 ( is 17.9m) Scale down suggests Indocin rev for Q1 2024 will be 6.19m or so (590 * 10.8)/1029 = 6.19m Mgmt already knew this in March ER as qtr was almost over no wonder they sized it as 18m-25m for the whole year. The sooner this runs down to zero and mkt focuses on Rolvedon and other patent protected portfolio we are better off.
IBUYSELLHOLD
Posted - 5 days ago
$ASRT / ATTENTION BARGAIN SHOPPERS !!! gotta love it
